Cargando…

Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease

Aggregation of α-synuclein (αSyn) plays a central role in the pathogenesis of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies (LBs) and Lewy neurites, which consist mainly of aggregated αSyn, are widely observed in the affected regions of patient brains. Except for some fam...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikenaka, Kensuke, Suzuki, Mari, Mochizuki, Hideki, Nagai, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619337/
https://www.ncbi.nlm.nih.gov/pubmed/31333408
http://dx.doi.org/10.3389/fnins.2019.00693
_version_ 1783433915943354368
author Ikenaka, Kensuke
Suzuki, Mari
Mochizuki, Hideki
Nagai, Yoshitaka
author_facet Ikenaka, Kensuke
Suzuki, Mari
Mochizuki, Hideki
Nagai, Yoshitaka
author_sort Ikenaka, Kensuke
collection PubMed
description Aggregation of α-synuclein (αSyn) plays a central role in the pathogenesis of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies (LBs) and Lewy neurites, which consist mainly of aggregated αSyn, are widely observed in the affected regions of patient brains. Except for some familial forms of PD/DLB, most sporadic PD/DLB patients express the wild-type (WT) αSyn protein without any mutations, and the mechanisms as to how WT αSyn gains the propensity to pathologically aggregate still remains unclear. Furthermore, the mechanisms by which the same αSyn protein can cause different synucleinopathies with distinct phenotypes and pathologies, such as PD, DLB, and multiple system atrophy (MSA), still remain largely unknown. Recently, mutations in the GBA1 gene (encoding glucocerebrosidase), which are responsible for the lysosomal storage disorder Gaucher disease (GD), have been reported to be the strongest risk factor for developing sporadic PD/DLB. We previously demonstrated that glucosylceramide accumulated by GBA1 deficiency promotes the conversion of αSyn into a proteinase K-resistant conformation. Furthermore, decreased glucocerebrosidase activity has also been reported in the brains of patients with sporadic PD/DLB. Moreover, αSyn pathology has also been shown in the brains of lysosomal storage disorder patients, which show glycosphingolipid accumulation. These observations suggest the possibility that altered lipid metabolism and lipid accumulation play roles in αSyn aggregation and PD/DLB pathogenesis. Indeed, several previous studies have demonstrated that lipid interactions affect the conformation of αSyn and induces its oligomerization and aggregation. In this review, we will give an overview of the association between αSyn aggregation and lipid interactions from the viewpoints of the etiology, pathology, and genetics of PD/DLB. We also discuss the distinct species of αSyn aggregates and their association with specific types of synucleinopathies, and introduce our hypothesis that lipid interactions play a role as trans-acting effectors in producing distinct strains of αSyn fibrils.
format Online
Article
Text
id pubmed-6619337
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66193372019-07-22 Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease Ikenaka, Kensuke Suzuki, Mari Mochizuki, Hideki Nagai, Yoshitaka Front Neurosci Neuroscience Aggregation of α-synuclein (αSyn) plays a central role in the pathogenesis of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies (LBs) and Lewy neurites, which consist mainly of aggregated αSyn, are widely observed in the affected regions of patient brains. Except for some familial forms of PD/DLB, most sporadic PD/DLB patients express the wild-type (WT) αSyn protein without any mutations, and the mechanisms as to how WT αSyn gains the propensity to pathologically aggregate still remains unclear. Furthermore, the mechanisms by which the same αSyn protein can cause different synucleinopathies with distinct phenotypes and pathologies, such as PD, DLB, and multiple system atrophy (MSA), still remain largely unknown. Recently, mutations in the GBA1 gene (encoding glucocerebrosidase), which are responsible for the lysosomal storage disorder Gaucher disease (GD), have been reported to be the strongest risk factor for developing sporadic PD/DLB. We previously demonstrated that glucosylceramide accumulated by GBA1 deficiency promotes the conversion of αSyn into a proteinase K-resistant conformation. Furthermore, decreased glucocerebrosidase activity has also been reported in the brains of patients with sporadic PD/DLB. Moreover, αSyn pathology has also been shown in the brains of lysosomal storage disorder patients, which show glycosphingolipid accumulation. These observations suggest the possibility that altered lipid metabolism and lipid accumulation play roles in αSyn aggregation and PD/DLB pathogenesis. Indeed, several previous studies have demonstrated that lipid interactions affect the conformation of αSyn and induces its oligomerization and aggregation. In this review, we will give an overview of the association between αSyn aggregation and lipid interactions from the viewpoints of the etiology, pathology, and genetics of PD/DLB. We also discuss the distinct species of αSyn aggregates and their association with specific types of synucleinopathies, and introduce our hypothesis that lipid interactions play a role as trans-acting effectors in producing distinct strains of αSyn fibrils. Frontiers Media S.A. 2019-07-03 /pmc/articles/PMC6619337/ /pubmed/31333408 http://dx.doi.org/10.3389/fnins.2019.00693 Text en Copyright © 2019 Ikenaka, Suzuki, Mochizuki and Nagai. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Ikenaka, Kensuke
Suzuki, Mari
Mochizuki, Hideki
Nagai, Yoshitaka
Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease
title Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease
title_full Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease
title_fullStr Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease
title_full_unstemmed Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease
title_short Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease
title_sort lipids as trans-acting effectors for α-synuclein in the pathogenesis of parkinson’s disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619337/
https://www.ncbi.nlm.nih.gov/pubmed/31333408
http://dx.doi.org/10.3389/fnins.2019.00693
work_keys_str_mv AT ikenakakensuke lipidsastransactingeffectorsforasynucleininthepathogenesisofparkinsonsdisease
AT suzukimari lipidsastransactingeffectorsforasynucleininthepathogenesisofparkinsonsdisease
AT mochizukihideki lipidsastransactingeffectorsforasynucleininthepathogenesisofparkinsonsdisease
AT nagaiyoshitaka lipidsastransactingeffectorsforasynucleininthepathogenesisofparkinsonsdisease